British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming sales figures in ...

We will deliver our fully reinvigorated portfolio to market efficiently and maximise the considerable commercial potential, ...

Two months later, GlaxoSmithKline (GSK) agreed to generate proprietary human liver datasets using Ochre’s computational biology, cellular, and perfused human organ platforms, in an up-to-$37.5 million ...

My father who passed away a while ago and his estate is going through probate. I would like to give our son a third of what I ...

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...

If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be ...

GSK has also taken the opportunity to throw out some of research products that were not producing results. Development of a PI3kb inhibitor, GSK2636771, has been terminated as part of the R&D rethink.

GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...

Every time the name changed, it provided work for local ... greatly to North Carolina’s life science future. Those GSK lab doors rattling shut are also going to open some new ones. New businesses. New ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...